Tucaxen Tucatinib 150 mg Tablet

TABLE OF CONTENT
Mode of Action
Indications
Dosage and Administration
Precautions
Side Effects

Tucaxen Tucatinib 150 mg Tablet is a cutting-edge medication meticulously engineered to target specific proteins involved in the growth and spread of cancer cells. Each tablet contains 150 mg of tucatinib, a potent tyrosine kinase inhibitor renowned for its efficacy in treating certain types of advanced or metastatic cancers.

Mode of Action: Tucatinib, the active ingredient in Tucaxen Tucatinib 150 mg Tablet, selectively inhibits the activity of human epidermal growth factor receptor 2 (HER2) and tyrosine kinase, key drivers of cancer cell proliferation and survival. By disrupting these signaling pathways, tucatinib helps suppress tumor growth and metastasis.

Indications: Tucaxen Tucatinib 150 mg Tablet is indicated for the treatment of:

• HER2-Positive Metastatic Breast Cancer
• HER2-Positive Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Dosage and Administration: The recommended dosage of Tucaxen Tucatinib 150 mg Tablet is one tablet (150 mg) to be taken orally twice daily with or without food. The dosage may vary based on individual patient factors and concurrent treatments. Patients should adhere strictly to the prescribed regimen provided by a healthcare professional.

Precautions:

• Prior to initiating treatment with Tucaxen Tucatinib 150 mg Tablet, patients should undergo thorough medical evaluation, including assessment of cardiac function and liver enzymes.
• Close monitoring of cardiac function, liver function, and gastrointestinal symptoms is essential during therapy.
• Tucatinib may interact with certain medications, so patients should inform their healthcare provider about all concurrent medications, including over-the-counter drugs and herbal supplements.

Side Effects: Common side effects associated with Tucaxen Tucatinib 150 mg Tablet may include:

• Diarrhea
• Nausea
• Fatigue
• Vomiting
• Elevated liver enzymes
• Decreased appetite
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)